Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267719 | 0.92 | ADRA1D (0.50) | ADRA1DKCNH2ADRA1AADRA1B | |
| SCHEMBL261226 | 0.90 | ADRA1D (0.48) | ADRA1DKCNH2ADRA1AADRA1B | |
| SCHEMBL261225 | 0.90 | ADRA1D (0.48) | ADRA1DKCNH2ADRA1AADRA1B | |
| SCHEMBL267691 | 0.90 | ADRA1D (0.51) | ADRA1DKCNH2ADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL261039 | 0.89 | ADRA1D (0.50) | ADRA1DKCNH2ADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL261040 | 0.89 | ADRA1D (0.50) | ADRA1DKCNH2ADRA1AADRA1B | |
| SCHEMBL280556 | 0.89 | ADRA1D (0.62) | ADRA1DKCNH2ADRA1AADRA1B | |
| SCHEMBL262259 | 0.87 | ADRA1D (0.46) | ADRA1DKCNH2ADRA1AADRA1B | |
| SCHEMBL262260 | 0.87 | ADRA1D (0.46) | ADRA1DKCNH2ADRA1AADRA1B | |
| SCHEMBL8569890 | 0.81 | ADRA1D (0.61) | ADRA1DKCNH2ADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120231541-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | Life Technologies Corporation (US) | 2012-09-13 | — | — | US | disclosed |
| US-8133695-B2 | Fluorescence polarization hERG assay | Life Technologies Corporation (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090253148-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | Life Technologies Corporation (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009108905-A2 | FLUORESCENCE POLARIZATION HERG ASSAY | Life Technologies Corporation (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253148-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | TNNI3, TNNT2, KCNQ1 | ADRA1D 593/4885KCNH2 9/4885ADRA1A 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.